Table 5.

Analysis of pro- and anti-inflammatory markers (MAKE365)

Pro- and Anti-Inflammatory MarkersPatients without MAKE365, d0Patients with MAKE365, d0P ValuePatients without MAKE365, d3Patients with MAKE365, d3P Value
MIF, median (Q1, Q3), pg/ml15,019.2 (10,189.2, 44,648.4)18,870.6 (9500.1, 45,180.3)0.9611,283.6 (5988.6, 23,681.1)95,32.2 (4881.6, 19,211.7)0.24
IL-6, median (Q1, Q3), pg/ml11,51.4 (354.1, 1794.9)967.4 (321.8, 2102.5)0.60282.7 (102.1, 552.1)253.7 (95.4, 687.4)0.81
IL-8, median (Q1, Q3), pg/ml313.6 (123.5, 571.2)256.6 (92.5, 538.5)0.7373.3 (30.9, 129.2)47.3 (25.5, 120.1)0.29
IL-10, median (Q1, Q3), pg/ml44.6 (20.8, 153.0)47.4 (18.3, 203.8)0.8522.2 (9.6, 48.6)16.8 (9.7, 52.9)0.91
IL-18, median (Q1, Q3), pg/ml727.0 (343.7, 1153.7)575.5 (285.0, 1376.7)0.63777.3 (350.9, 1849.6)539.8 (301.8, 1448.0)0.14
TNFR-1, median (Q1, Q3), pg/ml1600.3 (1221.1, 2104.9)1788.2 (1122.2, 2521.0)0.501447.8 (951.1, 2021.1)2023.4 (1200.5, 2995.0)<0.01
TNFR-2, median (Q1, Q3), pg/ml22,630.0 (14,873.8, 27,055.0)18,901.6 (12,856.0, 28,880.0)0.2320,880.0 (11,916.3, 29,420.0)24,820.0 (16,775.5, 39,677.5)<0.04
  • d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.